BioArctic AB's Second Quarter Report Invitation
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) is excited to announce the upcoming presentation of its second quarter report. This event is a significant opportunity for investors, analysts, and media to gain insights into the company's ongoing innovations in neurodegenerative diseases.
Details of the Presentation
The report will be published at 08:00 a.m. CET. At 09:30 CET, a live audiocast with teleconference will follow, featuring presentations from Gunilla Osswald, CEO, and Anders Martin-Löf, CFO. They will discuss the key outcomes of the quarter, offering valuable insights into the company’s performance and forward strategies.
Participating in the Audiocast
Interested participants can access the presentation via an online webcast, which will also allow for submitting written questions during the session. For those opting for the teleconference format, registration is essential, as it will provide unique access details, including phone numbers and a conference ID for direct interaction.
Webcast and Teleconference Access
For the audiocast, BioArctic encourages early registration to streamline the login process. Participants will have the chance to engage directly during the Q&A session, ensuring an interactive experience. The webcast will also be offered on demand following the live event, enabling those who missed it to catch up on important discussions and analysis.
Further Information on BioArctic AB
BioArctic AB is a Swedish biopharmaceutical company at the forefront of research aimed at treating neurodegenerative diseases. The company specializes in developing innovative treatments that enable delays or halts in disease progression. Their acclaimed drug, Leqembi® (lecanemab), is heralded as a groundbreaking treatment for early Alzheimer's disease, marking a pivotal advancement within the industry.
Innovations in Neurodegenerative Treatments
With a promising portfolio that includes therapies for Parkinson's disease and ALS, BioArctic is dedicated to pushing the boundaries of science in this field. Their proprietary BrainTransporter™ technology represents a significant leap forward by potentially facilitating the transport of antibodies across the blood-brain barrier, amplifying therapeutic efficacy.
Contact Information for Inquiries
For those seeking additional information on the presentation or other corporate matters, Oskar Bosson, VP Communications and Investor Relations, is available for inquiries via telephone.
Frequently Asked Questions
What is the date and time of the presentation?
The presentation will take place on August 28 at 09:30 a.m. CET.
Who will present the second quarter report?
Gunilla Osswald, CEO and Anders Martin-Löf, CFO will present the report.
How can I participate in the presentation?
You can join via the online webcast or attend through a teleconference after registering for details.
Will the presentation be available afterward?
Yes, the webcast will be available on demand on BioArctic’s corporate website after the live event.
What does BioArctic specialize in?
BioArctic focuses on innovative treatments for neurodegenerative diseases, particularly in Alzheimer’s disease, Parkinson's disease, and ALS.
